If you have been reading about freeze-thaw and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
In the kitchen, tempeh is often simply prepared by cutting it into pieces, soaking in brine or a salty sauce, and then fried. In Java, tempeh is often traditionally prepared by cutting it into pieces, marinating it in a mixture of ground garlic, coriander, turmeric, salt and water; then deep fried, and it's often served with sambal ulek chili paste. Cooked tempeh can be eaten alone, or used in chili, stir fries, soups, salads, sandwiches, and stews. Tempeh's complex flavor has been described as nutty, meaty, and mushroom-like. It freezes well, and is now commonly available in many western supermarkets, as well as in ethnic markets and health food stores. Tempeh can be steamed, marinated, thinly sliced, blackened, or crumbled into sauces and stews. Tempeh performs well in a cheese grater, after which it may be used in place of ground beef (as in tacos). When thin-sliced and deep-fried in oil, tempeh obtains a crisp golden crust while maintaining a soft interior. Its sponge-like consistency makes it suitable for marinating. Dried tempeh (whether cooked or raw) is more portable and less perishable and may be used as a stew base. Sometimes when tempeh is diced and left, it will create white feathery fluff which bonds the cut—this is the Rhizopus mold still growing—this is normal and perfectly edible.
=== Etymology === Ayahuasca is the hispanicized spelling (i.e., spelled according to Spanish orthography) of a word that originates from the Quechuan languages, which are spoken in the Andean states of Ecuador, Bolivia, Peru, and Colombia. Speakers of Quechuan languages who use modern Quechuan orthography spell it ayawaska. The word refers both to the liana Banisteriopsis caapi, and to the brew prepared from it. In the Quechuan languages, aya means 'spirit, soul', or 'corpse, dead body', and waska means 'rope' or 'woody vine, liana'. The word ayahuasca has been variously translated as 'liana of the soul', 'liana of the dead', and 'spirit liana'. In the cosmovision of its users, the ayahuasca is the vine that allows the spirit to wander detached from the body, entering the spiritual world, otherwise forbidden for the alive.
=== Synonyms === In 1838, Cantor proposed the name Hamadryas ophiophagus for the king cobra and explained that it has dental features intermediate between the genera Naja and Bungarus. Naia vittata proposed by Walter Elliot in 1840 was a king cobra caught offshore near Chennai that was floating in a basket. This provenance is disputed, as wild king cobras have never occurred near Chennai, and an analysis of this specimen has found it to be more similar to the northern king cobra. Hamadryas elaps proposed by Albert Günther in 1858 were king cobra specimens from the Philippines and Borneo. Günther considered both N. bungarus and N. vittata a variety of H. elaps. Naja ingens proposed by Alexander Willem Michiel van Hasselt in 1882 was a king cobra captured near Tebing Tinggi in northern Sumatra. The earliest scientific name for the king cobra was Naja bungaroides, given by Friedrich Boie in 1828 based on a juvenile specimen from Java. This description was improperly done, leaving it a nomen nudum at the time. However, Johann Georg Wagler validated the name in 1830 with a sufficient diagnosis, and also proposed a new genus for it, Hoplocephalus. In 1837, Hermann Schlegel used the name Naja bungaroides for his description of the Australian broad-headed snake, which was later reclassified into Wagler's Hoplocephalus, and used the species name Naja bungarus for the king cobra.
=== 1982–1994 === The company established its presence in the US in 1982 via a joint venture with Squibb Corporation and Canada in 1984. In 1985, the company introduced the first insulin pen device called Novopen. In 1989, Novo Industri (Novo Terapeutisk Laboratorium) and Nordisk Gentofte (Nordisk Insulinlaboratorium) merged to become Novo Nordisk, the world's largest producer of insulin with headquarters in Bagsværd, Greater Copenhagen. In 1991, Novo Nordisk Engineering (now NNE) demerged after working as in-house consultants at Novo for years, to provide standard engineering services (end-to-end engineering) to pharma manufacturing companies. In 1994, Novo's existing information technology units was spun out as NNIT. The company was converted into a wholly owned aktieselskab in 2004. In March 2015, NNIT was floated on the Nasdaq Nordic.
=== Mammalian === Mammalian tyrosinase is a single membrane-spanning transmembrane protein. In humans, tyrosinase is sorted into melanosomes and the catalytically active domain of the protein resides within melanosomes. Only a small, enzymatically inessential part of the protein extends into the cytoplasm of the melanocyte. As opposed to fungal tyrosinase, human tyrosinase is a membrane-bound glycoprotein and has 13% carbohydrate content. The derived TYR allele (rs2733832) is associated with lighter skin pigmentation in human populations. It is most common in Europe, but is also found at lower, moderate frequencies in Central Asia, the Middle East, North Africa, and among the San and Mbuti Pygmies.
Sources: en.wikipedia.org
== Original restaurant == The first In-N-Out restaurant that opened in 1948 was demolished when Interstate 10 (then US 60/US 70/US 99, the Ramona Freeway, now the San Bernardino Freeway) was built from downtown Los Angeles to the San Gabriel Valley. The freeway runs over the original location. A new restaurant was completed in 1954 near the original Baldwin Park, California, location. It was closed in November 2004 and demolished on April 16, 2011, despite discussions about using it as an In-N-Out museum chronicling the origins and history of the company. In-N-Out built a replacement restaurant on the other side of the freeway next to the original In-N-Out University (opened in 1984). A new In-N-Out University was built on the property. The university building houses the training department, which was moved from Irvine, California. In addition, the company restaurant was moved from In-N-Out's Baldwin Park headquarters to the new lot, which holds the restaurant and university, less than a thousand feet away. In 2014, a replica of the first In-N-Out was built in Baldwin Park.
== Human proteins containing laminin domains == Laminin domain I: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5) Laminin domain II: all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5) Laminin B (domain IV): all laminin alpha chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5), gamma chains (LAMC1, LAMC2, LAMC3), and perlecan (HSPG2) Laminin EGF-like (domains III and V): all laminin chains (LAMA1, LAMA2, LAMA3, LAMA4, LAMA5, LAMB1, LAMB2, LAMB3, LAMB4, LAMC1, LAMC2, LAMC3), attractins (ATRN, ATRNL1), cadherin EGF LAG seven-pass G-type receptors (CELSR1, CELSR2, CELSR3), cysteine-rich with EGF-like domain proteins (CRELD1, CRELD2), multiple EGF-like domain proteins (MEGF6, MEGF8, MEGF9, MEGF10, PEAR1), most netrins (NTN1, NTN3, NTN4, NTNG1, NTNG2), mucins 3A and 3B (MUC3A, MUC3B), class F scavenger receptors (SCARF1, SCARF2), stabilins (STAB1, STAB2), agrin (AGRIN), angiopoietin-1 receptor (TEK), perlecan (HSPG2), tenascin N (TNN), and usherin (USH2A).
mass number (A) Also atomic mass number or nucleon number. The total number of protons and neutrons (together known as nucleons) within the nucleus of an atom. It determines the atomic mass of the atom. Mass number varies between different isotopes of the same chemical element, and is often included either after the element's name (as in carbon-12) or as a superscript to the left of the element's symbol (as in 12C) to identify a specific isotope.
== Hybrid models == From the beginning, the cyclol reaction was considered as a covalent analog of the hydrogen bond. Therefore, it was natural to consider hybrid models with both types of bonds. This was the subject of Wrinch's fourth paper on the cyclol model (1936), written together with Dorothy Jordan Lloyd, who first proposed that globular proteins are stabilized by hydrogen bonds. A follow-up paper was written in 1937 that referenced other researchers on hydrogen bonding in proteins, such as Maurice Loyal Huggins and Linus Pauling. Wrinch also wrote a paper with William Astbury, noting the possibility of a keto-enol isomerization of the >CαHα and an amide carbonyl group >C=O, producing a crosslink >Cα-C(OHα)< and again converting the oxygen to a hydroxyl group. Such reactions could yield five-membered rings, whereas the classic cyclol hypothesis produces six-membered rings. This keto-enol crosslink hypothesis was not developed much further.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Dry powder is kept frozen, commonly at minus twenty degrees Celsius or below. It should be protected from light and moisture. Dissolved material is less stable and is generally used soon after preparation.